RESEARCH AND DEVELOPMENT

Our R&D initiatives are initially focused on the use of XENEX as a neuroprotectant in post-cardiac arrest syndrome (PCAS) patients. 

Following a successful in-hospital PCAS study, the focus will move to PCAS in a pre-hospital emergency response setting.  This opens the door to future indications in therapeutic areas such as Stroke, Traumatic Brain Injury, Anaesthesia Induced Developmental Neurotoxicity and Hypoxic Ischaemic Encephalopathy.

XENEX™ for Post Cardiac Arrest Syndrome

Post-Cardiac Arrest Syndrome (PCAS) Background

Cardiac arrest (CA), which is an abrupt cessation of blood flow to the body due to a failure of the heart to pump effectively, is often precipitated by a heart attack, which is related to blockage of blood flow to the heart.  Lack of blood-flow and hence oxygenation to the brain, known as hypoxia-ischaemia, causes neurological damage that often results in death. 

There are over 500,000 CA patients per year in the United States alone and over 600,000 in Europe. The majority of the CA events occur outside of the hospital and, in the US, resuscitation attempts occur in estimated 60% of these patients; in less than half of those patients does resuscitation successfully result in ROSC and transport to the hospital.

 

If the patient remains unconscious at hospital admission, they are considered to be suffering from Post-Cardiac Arrest Syndrome (‘‘PCAS’’) from the aggregate effects of both hypoxic/ischaemic (from the cardiac arrest) and reperfusion (from the successful resuscitation) injuries. The PCAS patient suffers further damage to vital organs, principally the brain and the heart, and survival to discharge from hospital occurs in fewer than 50%; death is most often from devastating brain injury.

 

There is currently no approved pharmacotherapy available for neuroprotection in PCAS patients. The current standard of care is targeted temperature management (TTM), also known as therapeutic hypothermia, administered for at least 24 hours in the critical care setting.

 

Extensive preclinical findings suggest that xenon is a promising neuroprotective therapy in hypoxic-ischaemic settings, especially when administered with hypothermia. The positive results of a Phase II Study (N=110) in out-of-hospital cardiac arrest (OHCA) patients corroborate the preclinical results.  NPXe hopes to replicate these findings in the larger pivotal Phase III Trial (XePOHCAS).

Pivotal Phase III XePOHCAS Trial

Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest (XePOHCAS)

TRIAL DESIGN: Randomised, controlled trial of ~1,400 patients in ~70 centres in North America and Europe

PATIENT POPULATION: Adult patients who benefited the most in Phase II study, i.e., those that had ROSC within 30 minutes

TREATMENT ARMS: XENEX™ plus Targeted Temperature Management (TTM) versus TTM-Alone

PRIMARY ENDPOINTS:  Survival & Functional Outcome (able to manage own affairs without assistance)

For more details, please visit clinicaltrials.gov (NCT03176186)

Pre-Hospital OHCA

Upon completion of the successful Phase III XePOHCAS Trial, studying the administration of xenon in the intensive care unit (ICU), NPXe plans to evaluate xenon administration in the pre-hospital emergency response setting.

XENEX™ Delivery System

Hospital Delivery Device

The XENEX™ Delivery System (XDS) delivers XENEX™ into a patented closed-breathing  inhalation system consisting of a proprietary gas controller, consumable circuit, ventilator, and a patient monitor.

Pre-Hospital Delivery Device

NPXe plans to develop a pre-hospital XDS to prosecute studying xenon in the pre-hospital emergency response setting.

DISCLAIMER – IMPORTANT

ELECTRONIC VERSIONS OF THE MATERIALS YOU ARE SEEKING TO WHICH THIS GATEPOST GIVES ACCESS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY NEUROPROTEXEON LIMITED (“NPXe”) IN GOOD FAITH AND ARE FOR INFORMATION PURPOSES ONLY.
THE MATERIALS TO WHICH THIS GATEPOST GIVE ACCESS ARE NOT DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN OR RESIDENT IN (OR ORGANISED OR INCORPORATED UNDER THE LAWS OF) THE UNITED STATES OR U.S. PERSONS (AS SUCH TERM IS DEFINED IN REGULATION S (“REGULATION S”) UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)), WHEREVER LOCATED, OR PERSONS RESIDENT OR LOCATED IN AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE THE EXTENSION OF AVAILABILITY OF THE MATERIALS TO WHICH YOU ARE SEEKING ACCESS WOULD BREACH ANY APPLICABLE LAW OR REGULATION.
The materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States, Australia, Canada, Japan, or in any jurisdiction in which such offers or sales are unlawful (the “Excluded Territories”) or to U.S. Persons (as such term is defined in Regulation S), wherever located. Any securities issued in connection with an offering have not been and will not be registered under the Securities Act or under any applicable securities laws of any state, province, territory, county or jurisdiction of the United States, Australia, Canada or Japan. Accordingly, unless an exemption under relevant securities laws is applicable, any such securities may not be offered, sold, resold, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, in or into the United States, Australia, Canada, Japan, or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration of such securities in, the relevant jurisdiction. There will be no public offer of securities in the United States.
The materials are only addressed to and directed at persons in member states of the European Economic Area (“EEA”) who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC and any amendments thereto including Directive 2010/73/EU to the extent implemented in the relevant EEA member state) and any relevant implementing measure in the relevant member state of the EEA (“Qualified Investors”). In addition, in the United Kingdom, the materials are being distributed only to, and are directed at Qualified Investors (as defined above) who are (a) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (b) high net worth entities, and other persons falling within Article 49(2)(a) to (d) of the Order to whom they may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). Any investment or investment activity to which these materials relates are available only to Relevant Persons in the United Kingdom and Qualified Investors in any member state of the EEA other than the United Kingdom, and will only be engaged with such persons.
If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. These materials must not be released or otherwise forwarded, distributed or sent to U.S. Persons or otherwise in or into the United States, Australia, Canada, Japan, or any jurisdiction in which such offers or sales are unlawful. Persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them to U.S Persons or otherwise in, into or from the United States, Australia, Canada or Japan.
Confirmation of understanding and acceptance of disclaimer
I warrant that I am not a resident of, or located in, the United States, Australia, Canada or Japan or any other jurisdiction where accessing these materials is unlawful, nor a U.S. Person, and I agree that I will not transmit or otherwise send any materials contained in this website to any U.S Person or any other person in the United States, Australia, Canada, Japan or any other jurisdiction where to do so would breach applicable local law or regulation.
I have read and understood the disclaimer set out above. I understand that it may affect my rights and I agree to be bound by its terms. I confirm that I am permitted to proceed to electronic versions of the materials.
NeuroproteXeon does not accept any responsibility for any contravention of applicable securities laws and regulations by individuals as a result of false information provided by such individuals.
[I ACCEPT] [DON’T ACCEPT]